What is the most likely diagnosis and recommended management for a 13-year-old boy with a one‑week history of cough, nasal congestion, hoarseness, mild sinus pressure, no fever or gastrointestinal symptoms, and increased short‑acting beta‑agonist (albuterol) inhaler use?

Most Likely Diagnosis: Viral Upper Respiratory Infection with Reactive Airway Disease/Asthma Exacerbation

This 13-year-old requires immediate optimization of his asthma control with inhaled corticosteroids (ICS), not just increased albuterol use, as the increased short-acting beta-agonist requirement signals inadequate anti-inflammatory treatment and risk for worsening exacerbation 1.

Clinical Assessment

The presentation—one week of cough, nasal congestion, hoarseness, sinus pressure, and escalating albuterol use without fever or systemic symptoms—is consistent with a viral upper respiratory infection triggering bronchial hyperreactivity in a patient with underlying asthma. The hoarseness likely reflects laryngeal inflammation from the viral infection and/or postnasal drip, though excessive albuterol use can also contribute 2.

Critical Red Flag: Increased Albuterol Use

The fact that this patient is using his albuterol inhaler "more often" is a warning sign of inadequate asthma control and impending exacerbation 3, 4. Research shows that 68% of caregivers inappropriately manage asthma exacerbations at home, with many undertreating despite perceiving severity 4. The FDA label explicitly warns that patients must seek medical evaluation if asthma worsens 3.

Immediate Management Algorithm

Step 1: Assess Current Asthma Control and Severity

• Determine baseline asthma status (intermittent vs. persistent)
• Quantify current albuterol use (number of puffs per day)
• Evaluate for signs of moderate-to-severe exacerbation (work of breathing, oxygen saturation, ability to speak in full sentences)

Step 2: Initiate or Optimize Inhaled Corticosteroids

For adolescents with chronic cough and increased bronchodilator requirements, inhaled corticosteroids are first-line treatment 1. The guideline specifically states that ICS should be considered first-line for cough variant asthma or when cough is the predominant symptom, with step-up dosing if response is incomplete 1.

• Start or increase ICS immediately (e.g., budesonide, fluticasone)
• Consider high-dose ICS given the current exacerbation
• If already on ICS, step up the dose
• Add leukotriene receptor antagonist (montelukast) if incomplete response to ICS 1

Step 3: Optimize Albuterol Use

Critical caveat: The albuterol label warns that excessive use can be life-threatening and that worsening symptoms require immediate medical evaluation 3. Proper technique and frequency must be verified:

• Albuterol should be used every 4-6 hours as needed, not more frequently without medical supervision 3
• Verify proper inhaler technique (many patients use inhalers incorrectly)
• Ensure spacer use if using metered-dose inhaler
• Do not exceed recommended dosing 3

Step 4: Address the Viral Upper Respiratory Component

For the cough and congestion symptoms themselves:

• Avoid over-the-counter cough and cold medications—guidelines explicitly recommend against their use in children/adolescents due to lack of efficacy and potential adverse events including death 5
• Avoid antihistamines—minimal to no efficacy for cough relief in children 5
• Avoid codeine-containing medications—risk of serious respiratory side effects 5
• Consider honey for symptomatic cough relief (though evidence is limited in adolescents) 5
• Nasal saline irrigation for congestion

Step 5: Consider Bacterial Sinusitis (Low Probability Here)

The mild sinus pressure with one week of symptoms does not meet criteria for acute bacterial sinusitis, which requires:

• Symptoms persisting >10 days without improvement, OR
• Severe symptoms (high fever ≥39°C, purulent nasal discharge) for 3-4 consecutive days, OR
• Worsening symptoms after initial improvement 6, 7

This patient does not require antibiotics at this time 6.

Follow-Up and Monitoring

• Reassess in 48-72 hours to evaluate response to ICS
• If no improvement or worsening despite ICS, consider:
  • Alternative diagnoses (pertussis, mycoplasma)
  • Step-up to ICS plus long-acting beta-agonist combination
  • Referral to pulmonology/allergy 7
• Monitor for complications: persistent fever, severe headache, facial swelling (orbital/intracranial complications of sinusitis are rare but serious) 6

Key Pitfalls to Avoid

1. Relying solely on albuterol without anti-inflammatory therapy—this is the most common error and leads to worse outcomes 1, 4
2. Using OTC cough/cold medications—no evidence of benefit and potential for harm 5
3. Prescribing antibiotics for viral symptoms—contributes to resistance without benefit 6
4. Ignoring increased albuterol use as a warning sign—this signals inadequate control and requires intervention 3, 4
5. Failing to verify inhaler technique—many patients use devices incorrectly, reducing efficacy

Return Precautions

Seek immediate care if:

• Difficulty breathing or speaking
• Chest retractions or accessory muscle use
• Albuterol needed more frequently than every 4 hours
• High fever develops (>39°C)
• Severe headache or facial swelling
• Symptoms persist beyond 10 days without improvement